Hubert Czerniak TV - Are you afraid of a HEART ATTACK? Take care of your HEART! Prevention and tr...

The speaker contrasts the older use of digitalis leaf preparations, which were dosed at 250 mg per tablet, with modern digoxin, which is available only in microgram tablets. He argues that this drastic dose reduction has rendered the therapy insufficient. He advocates returning to higher doses — at least two modern tablets per day. He acknowledges that digitalis must be loaded over about a week (saturation dosing) and that switching from strophanthin requires a washout period of several days. He links this protocol directly to the metabolic stress theory: by normalizing the autonomic nervous system and improving oxygen utilization, digoxin prevents the mismatch between oxygen supply and demand that triggers a heart attack. He also reiterates that everything is a poison depending on the dose, quoting Paracelsus, to preempt the toxicity argument.

The speaker tells the story of Dr. Kern's clinical trial with strophanthin in the Ruhr region. Over 15,000 patients received it, and only two suffered heart attacks — one due to a delayed dose during a mine accident. The results were so remarkable that newspapers reported them. He then describes the Heidelberg pronouncement, where the medical faculty declared strophanthin ineffective and toxic. He frames this as a deliberate suppression to protect beta-blocker sales. He also mentions Dr. Manfred von Ardenne, who held over 600 patents and worked with strophanthin and hyperthermia from the 1970s. The speaker acknowledges that strophanthin given intravenously acts very fast but briefly, unlike digitalis which requires loading. He presents it as a natural glycoside from Strophanthus seeds that modern cardiology ignores. He directs listeners to seek it as a preparation ('Strefa Anteny') as a practical way to implement this therapy.

The speaker argues that atherosclerosis is not solely caused by cholesterol but also by homocysteine, an amino acid that accumulates when protein metabolism lacks adequate B vitamins and minerals. He lists the necessary nutrients: vitamin B12 (specifically in its active methylcobalamin form, which bypasses MTHFR polymorphisms), vitamin B6, folic acid, vitamin B2, biotin, and nicotinic acid. He then introduces 'Pomocyna' as a product that contains all of these in their active forms, thereby removing the problem of methylation defects. He also emphasizes that pregnant women should take this exact preparation to ensure proper neural tube development. This protocol is positioned as a direct way to attack the atherosclerotic component of heart disease, complementing the stress-metabolic strategies with a nutritional intervention against plaque formation.

The speaker dedicates a significant portion to this protocol, framing it as a natural alternative to bypass surgery and valve replacement. He explains that matrix Gla protein is produced in response to vitamins D3 and A, but only vitamin K2 carboxylates it into its active calcium-binding form. Without K2, the uncarboxylated MGP cannot bind calcium, and instead, free calcium deposits in elastin fibers of the skin (wrinkles) and arteries (stiffening, plaque). He warns that standard medical advice to take D3 and calcium without K2 is a 'planned action' to damage arteries and cause heart disease. He then recommends a specific product from 'firma Sławi' as a convenient combined source. The protocol also encompasses joint decalcification: he states that Dupuytren's contractures (bent fingers) and rheumatoid arthritis deformities resolve because the same MGP mechanism removes calcium from the fibrotic nodules and joint capsules. He presents this as a unified theory of calcific disease: valves, arteries, kidneys, joints, and skin all respond to the K2-dependent MGP system.

The speaker brings up hyperbaric oxygen in the context of Dr. Manfred von Ardenne's work. Von Ardenne developed oxygen multi-step therapy and combined it with hyperthermia. The speaker notes that Poland now has over 70 hyperbaric chambers, making the therapy accessible. He frames it as a non-toxic, repeatable method for tackling hypoxia — not just in cancer (where it can re-oxygenate tumors and enhance radiosensitivity) but also in coronary artery disease and heart failure, where the entire metabolic problem revolves around oxygen deficit at the cellular level. The therapy is presented as supportive, used when conventional options fail, and as something that should always be 'in the back pocket' as a safe alternative.

The speaker credits Manfred von Ardenne (who held 600 patents and multiple honorary titles) with developing clinical hyperthermia from 1972 onward. He laments that despite its effectiveness, hyperthermia is used only secretly, in hospital basements, after all chemotherapy and radiation have been tried and failed. The therapy works by overheating tumors to over 40°C, causing their fragile, disorganized blood vessels to collapse while healthy tissue withstands the temperature. He mentions that von Ardenne also combined hyperthermia with oxygen multi-step therapy, suggesting a systemic approach that could benefit not only cancer but also heart conditions linked to hypoxia. Although he does not explicitly prescribe hyperthermia for heart attacks, the context of von Ardenne's integrated work and the discussion of oxygen therapy implies that he sees it as part of the same undervalued toolbox.

The speaker opens with the death of a colleague — a young dentist with no atherosclerotic changes at autopsy who left behind a small daughter. He states that such cases represent 40%, now up to 50%, of heart attacks. He traces the metabolic understanding to Dr. Berthold Kern, who noticed that many heart attack victims had clean coronaries, and to Hans Selye's stress theory. Selye showed that extreme sympathetic activation raises cardiac oxygen demand so much that even a normal blood supply becomes insufficient. The speaker explains that chronic stress — from an overbearing boss, threats, lockdowns, mask mandates — keeps the sympathetic system dominant, leading to tissue acidification, free radical damage, membrane injury, and ultimately a heart attack without any thrombotic occlusion. This is not presented as a fringe hypothesis but as a deliberately buried body of evidence that was sidelined when beta-blockers and other patented drugs entered the market. He connects the suppression of strophanthin (detailed separately) to the same forces that keep the metabolic theory out of medical education.

The speaker describes Dr. Kern's (often referred to in German literature as Dr. Berthold Kern) work in the Ruhr area. In a population of over 15,000 people given strophanthin, only two heart attacks occurred, and one of those was due to the patient not receiving the drug on time because of a mine accident. Newspapers celebrated the success. Subsequently, the medical faculty in Heidelberg convened and officially pronounced that strophanthin does not work for heart failure, does not prevent heart attacks, and is toxic, listing side effects. The speaker frames this as a direct consequence of the pharmaceutical industry wanting to protect beta-blockers and other patented drugs. He then draws a parallel to contemporary medicine, where effective non-patentable therapies are dismissed. He also mentions Dr. Manfred von Ardenne, a prolific physicist and inventor who worked on strophanthin and hyperthermia from 1972 onward, and who held over 600 patents, underscoring that serious scientists were invested in this approach.

The speaker draws attention to the parallel rising curves of statin sales and heart failure prevalence, suggesting a causal relationship. He explains that statins inhibit the mevalonate pathway, which not only produces cholesterol but also coenzyme Q10, a critical cofactor for mitochondrial electron transport and ATP production in heart muscle and skeletal muscle. Without sufficient CoQ10, the heart cannot properly utilize oxygen, leading to failure. He further claims that statins increase the frequency of Alzheimer's disease, kidney failure, liver failure, cancers, and rhabdomyolysis with intense pain. Even when standard liver function tests (AST/ALT) are normal, muscle biopsy shows rhabdomyolysis in 30% of people who report pain. This hidden muscle damage, he argues, is a silent epidemic caused by routine statin therapy.

The speaker explains the biochemistry: vitamins D3 and A induce the production of matrix Gla protein (MGP), but MGP is inactive until carboxylated by vitamin K2. Once activated, MGP binds free calcium and escorts it out of soft tissues — arterial walls, cardiac valves, kidney stones, rheumatic nodules, Dupuytren's contractures — and redeposits it into bones and teeth. He warns that mainstream advice to take D3 and calcium without K2 is disastrous; it leads to undercarboxylated MGP, causing calcification of elastin fibers, which manifests as wrinkles on the skin but also as stiffening and calcification of arteries. He cites American research where they administered 45 mg of vitamin K2 MK4, which is the animal-tissue form, suggesting that MK7 (from bacterial fermentation) is even more potent because of its longer half-life. For MK7, he says doses up to 1,000 mcg (1 mg) are safe, and according to some scientists, even higher. He claims that with this protocol, one does not need to operate on calcified valves or perform bypass surgery. The same process resolves Dupuytren's contracture (bent fingers) and rheumatic arthritis deformities.